Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Long-Term Durability of Response
Rapamycin (sirolimus, brand name Rapamune) is an mTORC1 inhibitor FDA-approved for renal transplant rejection prophylaxis and for lymphangioleiomyomatosis. Low-dose naltrexone (LDN) is a compounded, off-label preparation of naltrexone hydrochloride, an opioid receptor antagonist FDA-approved at 50 mg for opioid and alcohol use disorder, used off-label at 1.5 to 4.5 mg for pain and immune-modulatory purposes. Neither drug is FDA-approved for longevity, anti-aging, or general immune-modulation use in otherwise healthy adults, as of 2025.
The two drugs are frequently discussed together in longevity-medicine circles, but they are not competing treatments for the same problem. Rapamycin acts on a cell-intrinsic growth and aging pathway. LDN acts on opioid receptor signaling and downstream neuroimmune modulation. The useful comparison question is not which drug's effect lasts longer in some general sense, but which biological process, mTOR-driven cellular aging or neuroinflammatory/autoimmune signaling, actually matches the reader's clinical problem. Judged as interchangeable "longevity durability" options, both claims outrun what has been published: no controlled human trial of either drug in a healthy longevity population has run past roughly one year.
What is established, what is plausible, and what is not established
Established: Rapamycin inhibits mTORC1 and induces measurable changes in autophagy-related and immune-aging biomarkers over weeks to months in adults, based on published clinical pharmacology and short-to-medium duration trials. Low-dose naltrexone produces a transient opioid receptor blockade followed by a compensatory endorphin response, and multiple small controlled trials in pain and autoimmune conditions (fibromyalgia, multiple sclerosis, inflammatory bowel disease) have reported symptom benefit over trial durations of roughly 8 to 12 weeks. Neither drug is FDA-approved for the longevity or general immune-modulation use discussed on this page.
Plausible but unproven: That rapamycin's biomarker changes translate into meaningful reductions in age-related disease or mortality in healthy humans. That LDN's benefit in autoimmune or pain conditions generalizes to a "longevity" or general immune-optimization benefit in people without those conditions. That combining the two drugs produces additive or synergistic benefit; no published human trial has tested the combination.
Not established: Long-term (multi-year) durability of either drug's effect in a healthy, non-disease longevity population. Optimal long-term dose or schedule for either drug outside its approved indication. Whether stopping and restarting either drug repeatedly, a common longevity-clinic pattern, changes durability or risk.
Readers considering either drug outside its approved indication should treat published trial evidence as suggestive rather than conclusive, and should expect a prescribing clinician to say so plainly.
How each drug produces an effect that outlasts the dose
Sirolimus has a long terminal half-life (commonly cited in transplant pharmacology as in the range of two to three days), which supports once-weekly or every-other-week dosing while keeping mTORC1 activity suppressed across much of the interval. Weekly or intermittent rapamycin dosing has been studied in small human trials in older adults, with reported changes in immune-aging biomarkers and autophagy markers over roughly six to twelve months. Some of the specific effect sizes attributed to these trials in secondary or promotional sources (for example, a precise change in a composite "biological age" score) could not be verified against a primary publication for this draft and should be confirmed against the original trial report before being cited as a specific number to a patient.
Preclinical rodent studies, including work from the National Institute on Aging's Interventions Testing Program, have repeatedly reported lifespan extension in genetically heterogeneous mice given rapamycin later in life, even with time-limited dosing. This preclinical literature is well replicated across independent sites and is one of the more reproducible findings in aging biology, but replication in mice does not establish the same effect, dose, or safety profile in humans.
Low-dose naltrexone works on a different timescale. A single low dose occupies opioid receptors for roughly four to six hours; the following period of receptor rebound and compensatory endorphin release is thought to be where the anti-inflammatory and analgesic effects arise, through modulation of microglial and TLR4-related signaling. Clinical benefit in trials has generally taken six or more weeks to appear and has depended on consistent nightly dosing. Missing several consecutive doses is reported anecdotally to allow symptoms to drift back toward baseline within about a week, though this specific timeline comes from patient-reported experience rather than a controlled washout study, and should be described to patients as an approximation.
What the trial evidence actually supports
Small randomized and pilot studies of low-dose naltrexone have been published in fibromyalgia, multiple sclerosis, and inflammatory bowel disease, generally with sample sizes under 100 patients and trial durations of eight to twelve weeks, with some open-label extensions to around six months. These studies have generally reported statistically significant improvement in patient-reported pain or quality-of-life measures compared with placebo, though the magnitude of benefit varies by condition and study, and MRI or objective structural endpoints have not consistently shown corresponding change. A precise numeric readout (percent pain reduction, specific p-values) should not be repeated to patients without confirming it against the specific published paper, since several such figures circulating in secondary sources for LDN trials could not be independently verified for this draft.
For rapamycin, a small randomized trial in older adults has been discussed in longevity literature as evaluating weekly low-dose sirolimus against placebo over roughly a year, with reported effects on immune-aging and biomarker measures rather than hard clinical endpoints such as fracture, cardiovascular events, or mortality. As with the LDN literature, specific effect sizes reported in secondary sources should be verified against the primary trial publication before being used in patient-facing material. Readers and clinicians can check ClinicalTrials.gov directly for the current status and published results of ongoing rapamycin longevity trials.
The shared limitation across both drugs is real: no trial in either literature has been powered for, or has run long enough to capture, hard longevity or disease-incidence endpoints in a healthy population.
Side-effect profiles over time
Rapamycin's approved transplant labeling lists hyperlipidemia, impaired wound healing, and dose-dependent immunosuppression as recognized effects at continuous daily transplant dosing. Whether these risks are meaningfully attenuated at the much lower, intermittent weekly doses used off-label in longevity practice is plausible based on pharmacology but has not been established through long-term controlled safety data in that population. Mouth sores (aphthous-type stomatitis) are commonly reported by patients using weekly rapamycin off-label and generally improve with dose reduction or extended dosing intervals; this is a real-world clinical pattern rather than a formally quantified trial finding.
Low-dose naltrexone's reported side effects are milder in the published literature: transient vivid dreams and sleep disruption in a meaningful minority of new users, typically resolving within a few weeks. No serious adverse events attributable to naltrexone at 1.5 to 4.5 mg have been reported in the published controlled trials reviewed for this comparison. A firm clinical rule applies regardless of longevity context: patients taking opioid analgesics cannot use naltrexone, at any dose, without precipitating withdrawal. Rapamycin has no comparable opioid interaction, but it is a CYP3A4 and P-glycoprotein substrate, so drugs and foods that inhibit or induce those pathways (for example, strong CYP3A4 inhibitors or grapefruit juice, and inducers such as rifampin) can meaningfully change sirolimus blood levels and should be reviewed with a prescriber.
Which patient fits which drug: a decision framework
| Decision factor | Favors rapamycin | Favors LDN | Evidence status |
|---|---|---|---|
| Primary problem | Elevated biological-age biomarkers, interest in mTOR-linked cellular aging | Diagnosed neuroinflammatory or autoimmune condition (fibromyalgia, IBD, MS symptom burden), chronic pain | Rapamycin: small trials + strong rodent lifespan data. LDN: small RCTs in specific disease populations. Neither has hard longevity endpoints in humans. |
| Opioid status | No restriction from LDN interaction (other drug interactions still apply) | Must be completely opioid-free; naltrexone precipitates withdrawal in opioid users | Established pharmacology, not a probabilistic risk |
| Monitoring burden patient will accept | Willing to do periodic labs (lipids, CBC/CMP, possibly sirolimus trough) | Prefers minimal monitoring; LDN does not require routine blood levels | Site/clinical judgment, not a trial finding |
| Tolerance for immunosuppression-adjacent risk | Accepts theoretical wound-healing and immune risk even at low intermittent doses | Wants to avoid any degree of mTOR-related immune suppression, e.g. before elective surgery | FDA label describes risk at approved transplant dosing; risk at longevity pulse dosing is plausible but not separately quantified |
| Upcoming surgery or infection risk window | Caution or hold near elective surgery given wound-healing signal | No comparable surgical caution documented | FDA-approved transplant labeling |
| Time to expect a signal | Weeks for biomarker change; no established endpoint for a "durable" effect in healthy adults | Six to twelve weeks for symptom change in trial populations | Small trials, disease populations only |
| What stopping the drug does | Biological effect plausibly persists briefly (autophagy priming) before fading over weeks; not established in healthy longevity users | Symptom benefit reported to fade over roughly a week in patient reports, not a controlled washout study | Weak evidence on both sides; state uncertainty to patients |
| Regulatory status (as of 2025) | Off-label for longevity; FDA-approved only for transplant and LAM | Off-label at low dose; FDA-approved only at 50 mg for addiction | Confirm current label status before prescribing |
Patients with both an elevated aging-biomarker profile and an active inflammatory or autoimmune condition present a genuine judgment call. There is no published trial data on combining the two drugs. A reasonable, evidence-consistent approach discussed among longevity clinicians is to treat the more symptomatic or measurable problem first and reassess in several months, but this sequencing itself has not been tested in a controlled trial and should be framed to patients as clinical judgment, not established protocol.
Switching between the two drugs
A switch from rapamycin to LDN makes clinical sense when the goal shifts from mTOR-linked aging biology to immune or pain modulation, when rapamycin side effects (mouth sores, lipid changes) persist despite dose reduction, or when a patient develops a condition with actual LDN trial support, such as fibromyalgia. Naltrexone cannot be started in anyone currently using opioid analgesics; confirming opioid-free status is a prerequisite, not an optional check.
No pharmacokinetic interaction between sirolimus and naltrexone has been described, so a formal washout period is not required for drug-interaction reasons. A practical approach some clinicians use is to complete the current rapamycin weekly cycle, then begin naltrexone titration slowly (a low starting dose for one to two weeks, stepping up gradually) to reduce sleep disruption during adjustment. This is a clinical practice pattern rather than a trial-tested protocol. Patients should understand that LDN does not reproduce rapamycin's mTOR-suppression or autophagy effects; those effects are expected to fade over some weeks after stopping rapamycin, based on the pharmacology of mTOR signaling rather than a specific human washout study.
After switching, a reasonable monitoring approach is to recheck fasting lipids some weeks after stopping rapamycin to confirm any drug-related dyslipidemia is resolving, and to recheck inflammatory markers a few months after starting LDN to assess response. Specific intervals should be set with the prescribing clinician rather than taken as fixed rules from this page.
Dosing context, not a dosing instruction
This section describes patterns reported in the literature and in longevity-clinic practice; it is not a substitute for individualized prescribing. Rapamycin longevity dosing discussed in small trials and clinical practice has generally ranged from about 2 to 10 mg once weekly, sometimes extended to every other week; doses above that range have no published trial support for longevity use, and daily continuous dosing (the transplant regimen) is a substantially different pharmacological exposure with its own established risk profile per FDA-approved transplant labeling.
LDN is typically titrated from a low starting dose upward over several weeks to a maintenance dose in the 1.5 to 4.5 mg range, taken at bedtime; some protocols for specific autoimmune conditions use doses below 1.5 mg. Because no FDA-approved low-dose naltrexone product exists, all LDN is compounded, which carries the quality and consistency variability inherent to compounding pharmacies rather than manufacturer-controlled tablets.
Any actual starting dose, titration schedule, and monitoring plan should come from a prescriber who has reviewed the individual's full medical history, current medications, and lab work.
When to seek care rather than adjust either drug yourself
Anyone experiencing signs of infection, poor wound healing, unexplained shortness of breath, or significant mouth ulceration while on rapamycin should contact their prescriber promptly rather than simply skipping doses. Anyone on LDN who needs opioid pain control for surgery, injury, or acute illness should tell the treating clinician they are taking naltrexone, since it must be stopped before opioids can work and before opioids can safely be given. Neither drug substitutes for treatment of a diagnosed autoimmune disease, and worsening symptoms of an underlying condition warrant medical evaluation rather than a change in longevity-drug dosing.
Frequently asked questions
Should I switch from rapamycin to low-dose naltrexone? A switch is reasonable if the primary goal is immune or neuroinflammatory modulation rather than mTOR-linked aging biology, or if rapamycin side effects are not resolving with dose reduction. LDN will not reproduce rapamycin's autophagy-related effects.
Can rapamycin and LDN be taken together? No pharmacokinetic interaction has been described, but no published human trial has tested the combination. Any concurrent use would be empirical and should be closely supervised by a prescriber.
Is rapamycin FDA-approved for longevity? No. Rapamycin (Rapamune, sirolimus) is FDA-approved for renal transplant rejection prophylaxis and lymphangioleiomyomatosis. Longevity use is off-label.
Is low-dose naltrexone FDA-approved? Naltrexone is FDA-approved at 50 mg for opioid and alcohol use disorder. No dose below 50 mg has FDA approval; all LDN is a compounded, off-label preparation.
Which drug has more long-term human evidence? LDN has a longer real-world track record in disease populations (pain, MS, IBD case series and small trials over more than a decade), while rapamycin has stronger preclinical lifespan data and at least one recent trial in older adults assessing biomarkers. Neither drug has published human longevity outcome data extending meaningfully past about a year.
References
- FDA. Naltrexone Hydrochloride Tablets Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf
- ClinicalTrials.gov. Search for current and completed trials of rapamycin/sirolimus and of low-dose naltrexone: https://clinicaltrials.gov
Note for editorial and medical review: the source draft attached specific PubMed identifiers and precise effect sizes (biomarker changes, percentage pain reductions, p-values) and a direct quotation to named trials and a named researcher. These identifiers and the quotation could not be verified against primary literature during this revision and have been removed or converted to hedged, unlinked descriptions. Please verify the underlying trials (a small randomized rapamycin trial in older adults sometimes referenced as "PEARL," and the cited fibromyalgia, MS, and IBD naltrexone trials) against their original publications before restoring specific numbers or citations, and confirm whether the attributed quotation is genuine before any reinstatement.